Platform Technology
HumaMAX
We develop novel immunomodulatory materials based on our expertise in producing, isolating, and purifying poly-gamma-glutamic acid (γ-PGA), a natural biopolymer. This technology has wide applications in pharmaceuticals, functional foods, and cosmetics.
Poly-γ-glutamic acid(γ-PGA)
- Poly-gamma-glutamic acid (PGA) is a natural, edible amino acid polymer discovered in traditional fermented foods.
- Produced by Bacillus subtilis Chungkookjang, a GRAS (Generally Recognized as Safe) microorganism with established food safety
- Natural high molecular weight material produced through our proprietary manufacturing method (Certified as one of Korea's top 10 new technologies)
- This high-molecular-weight natural substance enhances human immune function, demonstrating anti-cancer, anti-viral, and anti-inflammatory properties, leading to its development as multiple drug candidates.
- PGA-K has been recognized as a functional ingredient for immune enhancement in health functional foods4.
- Additionally, it serves as an effective cosmeceutical ingredient, offering excellent moisturizing properties, skin barrier improvement, and anti-wrinkle functions while boosting skin immunit
Development of new drugs based on immune regulation efficacy of natural amino acid polymer bioactive material “γ-PGA (Poly-γ-glutamic Acid)
- Structure composed of gamma-peptide bonded glutamic acid, an essential amino acid
- Immune modulation via TLR4: ① enhances innate and ② adaptive immunity, ③ improves tumor microenvironment
- Boosts NK cell activity for superior immune enhancement
- Excellent safety profile derived from GRAS microbial fermented foods
Platform Technology
MucoMAX
A new concept of immunotherapy that uses probiotics as carriers to treat diseases by inducing mucosal immune responses
- Development of expression modules for surface display of target proteins, allowing flexibility through module replacement for different targets.
- Excellent safety profile due to the use of Generally Recognized as Safe (GRAS) microorganisms.
- Induction of antibody production through mucosal immune responses, in addition to the immune-enhancing effects of probiotics.
- Lower production costs compared to conventional biopharmaceuticals.
Oral therapeutic and preventive vaccine development platform technology
- Probiotics are used as carriers to deliver antigens (whole proteins or peptide fragments) through the small intestine's mucous membrane into the body. This process induces antigen-specific immune responses
- The method can trigger either antigen-specific Cytotoxic T Lymphocyte (CTL) immune responses or antibody production.
* Key immunological feature: It stimulates the body's natural antigen-antibody reactions to neutralize and remove target proteins or increase cytotoxic activity to eliminate abnormal cells, thus preventing or treating diseases and symptoms.
- Depending on the surface expression module, it's possible to express either single or dual targets.
Scalability
Our versatile expression modules offer exceptional scalability, enabling both single and multi-target expression tailored to specific targets.
Safety
It provides excellent safety by using proven probiotics as a carrier.
Convenience
Unlike existing vaccines, it does not require an adjuvant, and is convenient to take as it is administered orally
